Technical Data
045163
PP1 (4-Amino-5-(methylphenyl)-7-(tert.butyl)pyrazolo-(3,4-d)pyrimidine)
1mg
Biochemicals Storage: 4C/-20CShipping: Blue Ice
Highly potent and selective Scr family tyrosine kinase inhibitor. Shows anti-Ras cancer potential by blocking Ras-induced activation of PAK1. Antitumor compound. RIP2 inhibitor. Blocks TGF-beta-mediated cellular responses.

Storage and Stability:
Short-term Storage: +4C
Long-term Storage: -20C
Working aliquots are stable for up to 3 months when stored at -20C. Stable for at least 2 years after receipt when stored at -20C.

CAS Number:
172889-26-8

Molecular Formula:
C16H19N5

Molecular Weight:
281.40
Purity: >98% (HPLC)

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference:
Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation: J.H. Hanke, et al.; J. Biol. Chem. 271, 695 (1996)
Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilonRI- and Thy-1-mediated activation of rat basophilic leukemia cells: M. Amoui, et al.; Eur. J. Immunol. 27, 1881 (1997)
Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1: G.W. Krystal, et al.; Cancer Res. 58, 4660 (1998)
An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies: H. He, et al.; Cancer J. 6, 243 (2000)
The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes: F. Carlomagno, et al.; Cancer Res. 62, 1077 (2002)
The specificities of protein kinase inhibitors: an update: J. Bain, et al.; Biochem. J. 371, 199 (2003)
The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases: L. Tatton, et al.; J. Biol. Chem. 278, 4847 (2003)
Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II: M. Maeda, et al.; J. Biol. Chem. 281, 59 (2006)
The selectivity of protein kinase inhibitors: a further update: J. Bain, et al.; Biochem. J. 408, 297 (2007)
The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors: H. Ungefroren, et al.; Curr. Cancer Drug Targets 11, 524 (2011)


Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.